Cart
0

Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class (Alpha Blocker, 5- Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others), and Therapy (Mono Drug Therapy and Combination Drug Therapy) - Global Opportunity Analysis and Industry Forecast, 2018-2025

Get 20% Free Customization In This Report
LI_184708
Pages: 205
Jul 2018 | 670 Views
 
Author's : Mayuri Srivastava & Pallavi Jaiswal
Tables: 89
Charts: 47
 

Benign Prostatic Hyperplasia Therapeutics Market Overview:

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Benign prostatic hyperplasia (BPH) is a medical condition involving enlargement of the prostate gland and is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from an uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, weak urinary system, and inability to empty the urinary bladder. Currently, medications are the common way to treat men with mild to moderate BPH. Treatment with drugs, such as alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, antimuscarinics, and others, offers a way of avoiding or postponing surgery. These types of drugs are considered as the most appropriate first-line treatment of the BPH condition.

Get more information on this report : Request Sample Pages

Market Dynamics

The growth of the global benign prostatic hyperplasia therapeutics market is majorly driven by the increase in male geriatric population. Other factors boosting the market growth include rise in awareness about prostate cancer and other urological disorders and increase in occurrence of benign prostatic hyperplasia patients across the world. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hampers the market growth. Conversely, presence of strong pipeline products and high potential in untapped markets of the emerging economies are expected to provide lucrative growth opportunities for the global benign prostatic hyperplasia therapeutics market.

Market Segmentation

The global benign prostatic hyperplasia therapeutics market is segmented into therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. The alpha blocker segment accounted for the largest market share in 2017, and is expected to remain dominant throughout the forecast period, owing to high preferability and large number of alpha blocker drugs across various economies.

Get more information on this report : Request Sample Pages

By therapy, the global benign prostatic hyperplasia therapeutics market is bifurcated into mono drug therapy and combination drug therapy. The mono drug therapy segment accounted for the largest market share in 2017, owing to high usage of this type of therapy because most of the drugs are employed alone for the treatment of the benign prostatic hyperplasia condition. On the other hand, the combination drug therapy segment is expected to grow at a CAGR of 9.6% during the forecast period.

Get more information on this report : Request Sample Pages

Based on region, the global benign prostatic hyperplasia therapeutics industry is studied across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA). North America held the largest share of the market in 2017, followed by Europe. On the other hand, the Asia-Pacific region is anticipated to dominate the market during the forecast period, owing to high population base, increase in disposable income, and enhanced patient awareness about the benign prostatic hyperplasia condition. Moreover, Asia is a large continent and has emerged as an epicenter of a large percentage of male geriatric population.

Get more information on this report : Request Sample Pages

The key players of the global benign prostatic hyperplasia therapeutics market include Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited.

Other players (these players are not profiled in the report and the same can be included on request) in the value chain include Nymox Pharmaceutical Corporation, Protox Therapeutics, Inc., terna Zentaris, and Urologix, LLC.

Key Benefits

  • The study provides an in-depth analysis of the global benign prostatic hyperplasia therapeutics market trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
  • A comprehensive analysis of factors that drive and restrict the global benign prostatic hyperplasia therapeutics market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global and regional scales are provided.
  • The profiles of the key players and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Benign Prostatic Hyperplasia Therapeutics Market Key Segments:

By Product

  • Alpha blocker
  • 5-Alpha reductase inhibitor
  • Phosphodiesterase-5 inhibitor
  • Others

By Therapy

  • Mono drug therapy
  • Combination drug therapy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Porter’s Five Forces analysis

3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in in geriatric population
3.5.1.2. Rise in prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the awareness related to urological disorders and prostate cancer

3.5.2. Restraints

3.5.2.1. High preferences for minimally invasive surgical therapies

3.5.3. Opportunities

3.5.3.1. Large number of products in pipeline
3.5.3.2. Opportunities in emerging economies

3.5.4. Impact analyses

3.6. Clinical trials

Chapter: 4: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Alpha Blockers

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. 5-Alpha Reductase Inhibitors

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Phosphodiesterase 5 Inhibitor

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Others

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

Chapter: 5: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY

5.1. Overview

5.1.1. Market size and forecast

5.2. Mono Drug Therapy

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Combination Drug Therapy

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

Chapter: 6: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America benign prostatic hyperplasia therapeutics market, by country

6.2.2.1. U.S.

6.2.2.1.1. Market size and forecast, by therapeutic class
6.2.2.1.2. Market size and forecast, by therapy

6.2.2.2. Canada

6.2.2.2.1. Market size and forecast, by therapeutic class
6.2.2.2.2. Market size and forecast, by therapy

6.2.2.3. Mexico

6.2.2.3.1. Market size and forecast, by therapeutic class
6.2.2.3.2. Market size and forecast, by therapy

6.2.3. North America market size and forecast, by therapeutic class
6.2.4. North America market size and forecast, by therapy

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Market size and forecast, by therapeutic class
6.3.2.1.2. Market size and forecast, by therapy

6.3.2.2. France

6.3.2.2.1. Market size and forecast, by therapeutic class
6.3.2.2.2. Market size and forecast, by therapy

6.3.2.3. UK

6.3.2.3.1. Market size and forecast, by therapeutic class
6.3.2.3.2. Market size and forecast, by therapy

6.3.2.4. Italy

6.3.2.4.1. Market size and forecast, by therapeutic class
6.3.2.4.2. Market size and forecast, by therapy

6.3.2.5. Spain

6.3.2.5.1. Market size and forecast, by therapeutic class
6.3.2.5.2. Market size and forecast, by therapy

6.3.3. Rest of Europe

6.3.3.1.1. Market size and forecast, by therapeutic class
6.3.3.1.2. Market size and forecast, by therapy

6.3.4. Europe market size and forecast, by therapeutic class
6.3.5. Europe market size and forecast, by therapy

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Market size and forecast, by therapeutic class
6.4.2.1.2. Market size and forecast, by therapy

6.4.2.2. China

6.4.2.2.1. Market size and forecast, by therapeutic class
6.4.2.2.2. Market size and forecast, by therapy

6.4.2.3. India

6.4.2.3.1. Market size and forecast, by therapeutic class
6.4.2.3.2. Market size and forecast, by therapy

6.4.2.4. Australia

6.4.2.4.1. Market size and forecast, by therapeutic class
6.4.2.4.2. Market size and forecast, by therapy

6.4.2.5. South Korea

6.4.2.5.1. Market size and forecast, by therapeutic class
6.4.2.5.2. Market size and forecast, by therapy

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Market size and forecast, by therapeutic class
6.4.2.6.2. Market size and forecast, by therapy

6.4.3. Asia-Pacific market size and forecast, by therapeutic class
6.4.4. Asia-Pacific market size and forecast, by therapy

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Market size and forecast, by therapeutic class
6.5.2.1.2. Market size and forecast, by therapy

6.5.2.2. Saudi Arabia

6.5.2.2.1. Market size and forecast, by therapeutic class
6.5.2.2.2. Market size and forecast, by therapy

6.5.2.3. South Africa

6.5.2.3.1. Market size and forecast, by therapeutic class
6.5.2.3.2. Market size and forecast, by therapy

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Market size and forecast, by therapeutic class
6.5.2.4.2. Market size and forecast, by therapy

6.5.3. LAMEA market size and forecast, by therapeutic class
6.5.4. LAMEA market size and forecast, by therapy

Chapter: 7: COMPANY PROFILES

7.1. Abbott Laboratories

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance

7.2. Allergan plc

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance

7.3. Astellas Pharma Inc.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance

7.4. Boehringer Ingelheim Pharma GmbH & Co. KG

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance

7.5. Eli Lilly and Company

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance

7.6. GlaxoSmithKline plc.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance

7.7. Merck & Co., Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance

7.8. Pfizer Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance

7.9. Sanofi

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. Teva Pharmaceutical Industries Limited

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

 LIST OF TABLES

TABLE 01. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 02. GLOBAL ALPHA BLOCKERS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 03. GLOBAL 5-ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 04. GLOBAL PHOSPHODIESTERASE 5 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. GLOBAL OTHER BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 07. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY MONO DRUG THERAPY, BY REGION, 2017-2025 ($MILLION)
TABLE 08. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY COMBINATION DRUG THERAPY, BY REGION, 2017-2025 ($MILLION)
TABLE 09. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 10. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 11. U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 12. U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 13. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 14. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 15. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 16. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 17. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 18. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 19. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 20. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 21. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 22. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 23. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 24. UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 25. UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 26. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 27. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 28. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 29. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 30. REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 31. REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 32. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 33. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 34. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 35. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 36. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 37. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 38. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 39. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 40. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 41. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 42. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 43. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 44. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 47. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 48. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 49. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 50. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 51. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 52. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 53. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 54. SOUTH ARICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 55. SOUTH ARICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 56. REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 57. REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 58. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 59. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2017-2025 ($MILLION)
TABLE 60. ABBOTT: COMPANY SNAPSHOT
TABLE 61. ABBOTT: OPERATING SEGMENTS
TABLE 62. ABBOTT: PRODUCT PORTFOLIO
TABLE 63. ALLERGAN: COMPANY SNAPSHOT
TABLE 64. ALLERGAN: OPERATING SEGMENTS
TABLE 65. ALLERGAN: PRODUCT PORTFOLIO
TABLE 66. ASTELLAS: COMPANY SNAPSHOT
TABLE 67. ASTELLAS: PRODUCTS AND SERVICES
TABLE 68. ASTELLAS: PRODUCT PORTFOLIO
TABLE 69. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 70. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 71. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 72. LILLY: COMPANY SNAPSHOT
TABLE 73. LILLY: OPERATING SEGMENTS
TABLE 74. LILLY: PRODUCT PORTFOLIO
TABLE 75. GSK: COMPANY SNAPSHOT
TABLE 76. GSK: OPERATING SEGMENTS
TABLE 77. GSK: PRODUCT PORTFOLIO
TABLE 78. MERCK: COMPANY SNAPSHOT
TABLE 79. MERCK: OPERATING SEGMENTS
TABLE 80. MERCK: PRODUCT PORTFOLIO
TABLE 81. PFIZER: COMPANY SNAPSHOT
TABLE 82. PFIZER: OPERATING SEGMENTS
TABLE 83. PFIZER: PRODUCT PORTFOLIO
TABLE 84. SANOFI: COMPANY SNAPSHOT
TABLE 85. SANOFI: OPERATING SEGMENTS
TABLE 86. SANOFI: PRODUCT PORTFOLIO
TABLE 87. TEVA: COMPANY SNAPSHOT
TABLE 88. TEVA: OPERATING SEGMENTS
TABLE 89. TEVA: PRODUCT PORTFOLIO

 LIST OF FIGURES

FIGURE 01. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. BARGANING POWER OF BUYERS
FIGURE 05. BARGANING POWER OF SUPPLIERS
FIGURE 06. THREAT OF SUBSTITUTION
FIGURE 07. THREAT OF NEW ENTRANT
FIGURE 08. COMPETITIVE RIVALRY
FIGURE 09. IMPACT ANALYSES
FIGURE 10. CLINICAL TRIALS IN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION
FIGURE 11. CLINICAL TRIALS IN BPH THERAPEUTICS MARKET, NORTH AMERICA
FIGURE 12. COMPARATIVE ANALYSIS OF ALPHA BLOCKERS MARKET, 2017 & 2025 (PERCENTAGE)
FIGURE 13. COMPARATIVE ANALYSIS OF 5-ALPHA REDUCTASE INHIBITORS MARKET, 2017 & 2025 (PERCENTAGE)
FIGURE 14. COMPARATIVE ANALYSIS OF PHOSPHODIESTERASE 5 INHIBITOR MARKET, 2017 & 2025 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF OTHER BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, 2017 & 2025 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY MONO DRUG THERAPY, 2017 & 2025 (PERCENTAGE)
FIGURE 17. COMPARATIVE ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET BY COMBINATION DRUG THERAPY, 2017 & 2025 (PERCENTAGE)
FIGURE 18. COMPARISON OF MALE GERIATRIC POPULATION IN EUROPEAN COUNTRIES FOR THE YEAR 2017, IN MILLION
FIGURE 19. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 20. ABBOTT: NET SALES SHARE BY OPERATING SEGMENT, 2017 (%)
FIGURE 21. ABBOTT: NET SALES SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. ALLERGAN: REVENUE, 2015-2017 ($MILLION)
FIGURE 23. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24. ASTELLAS: SALES, 2015-2017 ($MILLION)
FIGURE 25. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)
FIGURE 26. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. BOEHRINGER INGELHEIM: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. BOEHRINGER INGELHEIM: NET SALES BY BUSINESS, 2017 (%)
FIGURE 29. BOEHRINGER INGELHEIM: NET SALES BY REGION, 2017 (%)
FIGURE 30. REVENUE, 2015-2017 ($MILLION)
FIGURE 31. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. LILLY: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 33. GSK: REVENUE, 2015-2017 ($MILLION)
FIGURE 34. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 36. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 38. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 39. PFIZER: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 45. TEVA: REVENUE, 2015-2017 ($MILLION)
FIGURE 46. TEVA: REVENUE BY SEGMENT, 2017 (%)
FIGURE 47. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

Benign prostatic hyperplasia (BPH) is characterized by enlargement of the prostate gland. This, in turn, occurs owing to proliferation of the cellular elements of the prostate. According to various studies, it is estimated that the average percentage of prevalence of benign prostatic hyperplasia across the world is 50% to 60% for men in their 60s and 80% to 90% for men in their 70s. Several benign prostatic hyperplasia treatment options are developed, among which benign prostatic therapeutics are employed to treat mild to severe benign prostatic hyperplasia conditions. These medications include alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others.

The escalating number of benign prostatic hyperplasia patients is the major factor that drives the growth of the global benign prostatic hyperplasia therapeutic market. Relevant factors, such as increase in geriatric population across the globe and rise in awareness related to urological disorders and prostate cancer, are expected to have a significant impact on the growth of the market. However, patients have been increasingly adopting minimally-invasive surgical therapies than BPH therapeutics, which is anticipated to impede the market growth.

The use of benign prostatic hyperplasia therapeutics is the highest in North America, owing to a large geriatric population and high prevalence and awareness among public related to benign prostatic hyperplasia, which is followed by Europe and Asia-Pacific. In addition, abundance of pipeline products for treatment of benign prostatic hyperplasia is anticipated to drive the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Benign Prostatic Hyperplasia Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2018-2025

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo